Seattle, WA (PRWEB) June 13, 2013
Quorum Review IRB, the industry leader in central IRB services, announces its Executive Vice-Chair, Royce A. Morrison, MD, MS, as a presenter and panel chair at the Drug Information Association’s 49th Annual Meeting. This year DIA is held in Boston, MA, June 23-27, 2013.
Dr. Morrison chairs his first session “First-in-Human Studies: How Much Complexity Is Too Much?” on Tuesday, June 25 at 1:45 p.m. The meeting topic includes trends that disrupt standard early-phase sequences and drive study complexity, and the best practices to mitigate risks. Dr. Morrison focuses on “The IRB: Regulatory Protection” in his portion of the presentation. On Wednesday, June 26 at 10:15 a.m., Dr. Morrison chairs the session, “Pharmacometrics: Implications and Impact in Preclinical to Early Phase Clinical Development,” where panelists discuss the discipline of pharmacometrics in drug development and regulatory decision-making. Dr. Morrison will present “Opportunities to Take Advantage of Pharmacometrics” during that session. Later that afternoon at 4:00 p.m., he heads the panel discussion for “Pharmacometric Methods: Essential for Optimal Drug Development Strategy”. This session defines pharmacometrics and describes examples of its application across the range of drug and development and decision-making activities.
Dr. Morrison serves as Executive Vice-Chair on Quorum’s Review Board and is board certified in internal medicine as well as a Certified Physician Investigator by the Academy of Pharmaceutical Physicians and Investigators. He earned his MD degree at Stanford University and has practiced in both private and HMO settings, emphasizing geriatrics and HIV/AIDS. Dr. Morrison has been a member of the Board of Association of Clinical Pharmacology Units, and is Past President and Board member of the Northwest Association for Biomedical Research.
The DIA Annual Meeting is the largest multidisciplinary event that brings together a global network of professionals to foster innovation that will lead to the development of safe and effective medical products and therapies. More information about the 2013 conference is available on the DIA website.
For the latest on Quorum Review News and Events, visit http://www.quorumreview.com.
About Quorum Review IRB
Quorum Review is an independent review board fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and has been providing IRB review of drug and device trials since 1992. Quorum oversees research in accordance with U.S. and Canadian human subject research protection regulations and guidelines set forth by the International Committee on Harmonisation (ICH), and principles of the Belmont Report.
Quorum’s best-in-class IRB services include 14 Board meetings each week plus expedited review, 24-hour site review turnaround, 36-hour amendment review turnaround, a secure web portal, and Smart Forms for online submissions. Quorum’s IRB service offerings include full study review in the US and Canada, a specialized Phase I team, and unique processes for post-approval and registry studies.